These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

831 related items for PubMed ID: 10066640

  • 21. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K.
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [Abstract] [Full Text] [Related]

  • 22. Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.
    Portilla J, Boix V, Garcia-Henarejos JA, Llopis C, Martínez-Madrid O, Gimeno A, Sánchez-Paya J, Merino E.
    Int J STD AIDS; 2005 Dec; 16(12):807-10. PubMed ID: 16336763
    [Abstract] [Full Text] [Related]

  • 23. Salvage therapy studies.
    Proj Inf Perspect; 1998 Sep; (25):7. PubMed ID: 11365850
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, Study Team.
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [Abstract] [Full Text] [Related]

  • 26. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B, Staccato Study Group.
    Antivir Ther; 2005 Jun; 10(6):761-7. PubMed ID: 16218176
    [Abstract] [Full Text] [Related]

  • 27. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P, Likanonsakul S.
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [Abstract] [Full Text] [Related]

  • 28. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, Moreno S, NELSANE Study.
    AIDS Res Hum Retroviruses; 2001 Jan 20; 17(2):93-8. PubMed ID: 11177388
    [Abstract] [Full Text] [Related]

  • 29. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, Bart PA, Miller V, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JM, Lazzarin A, Pantaleo G.
    J Clin Invest; 2000 Mar 20; 105(6):777-82. PubMed ID: 10727446
    [Abstract] [Full Text] [Related]

  • 30. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
    Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M.
    Antimicrob Agents Chemother; 2007 Jun 20; 51(6):2035-42. PubMed ID: 17371813
    [Abstract] [Full Text] [Related]

  • 31. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.
    Casado JL, Moreno S, Hertogs K, Dronda F, Antela A, Dehertogh P, Perez-Elías MJ, Moreno A, NELSANE study.
    AIDS; 2002 Jan 04; 16(1):47-52. PubMed ID: 11741162
    [Abstract] [Full Text] [Related]

  • 32. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.
    Smith D, Hales G, Roth N, Law M, Ray J, Druett J, Mitchell J, Mills G, Doong N, Franklin R, CHRN 025 Study Group. Community HIV Research Network.
    HIV Clin Trials; 2001 Jan 04; 2(2):97-107. PubMed ID: 11590517
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
    Hellinger JA, Cohen CJ, Stein AJ, Gallant JE, Gathe J, Keiser P.
    HIV Clin Trials; 2000 Jan 04; 1(2):25-8. PubMed ID: 11590495
    [Abstract] [Full Text] [Related]

  • 34. [Importance of antiproteases in the treatment of microsporidia and/or cryptosporidia infections in HIV-seropositive patients].
    Bobin S, Bouhour D, Durupt S, Boibieux A, Girault V, Peyramond D.
    Pathol Biol (Paris); 1998 Jun 04; 46(6):418-9. PubMed ID: 9769873
    [Abstract] [Full Text] [Related]

  • 35. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L.
    N Engl J Med; 1996 Apr 18; 334(16):1011-7. PubMed ID: 8598838
    [Abstract] [Full Text] [Related]

  • 36. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 37. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA.
    J Infect Dis; 1999 Jun 10; 179(6):1375-81. PubMed ID: 10228057
    [Abstract] [Full Text] [Related]

  • 38. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA, AIDS Clinical Trials Group 364 Study Team.
    N Engl J Med; 2001 Aug 09; 345(6):398-407. PubMed ID: 11496850
    [Abstract] [Full Text] [Related]

  • 39. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.
    HIV Clin Trials; 2005 Aug 09; 6(5):235-45. PubMed ID: 16306030
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.